Published on 21/12/2025
Labeling Multilingual Compliance – Best Practices for FDA & EMA
Introduction: Why Multilingual Labeling Matters in Global Clinical Trials
As clinical trials expand across borders, the need for sample labels in multiple languages has become essential. Accurate and compliant labeling not only ensures sample traceability and safe transport but also meets the regulatory requirements of country-specific authorities. Incorrect or poorly translated labels can lead to customs rejections, site confusion, or sample mismanagement—each of which can result in regulatory findings.
Both the FDA and EMA emphasize that labeling practices for clinical samples should be clear, unambiguous, and appropriate for the region in which the study is being conducted. Sponsors must ensure that labeling SOPs account for local language needs, translation controls, and consistent label design.
Regulatory Requirements for Sample Labeling
According to ICH E6(R2) and Annex 13 of the EU GMP Guidelines, labeling for investigational materials (including clinical samples) must:
- Be understandable
In multi-regional trials, this means labels may need to be presented in English plus the local language (e.g., Spanish, French, Japanese), particularly for sample collection kits and shipping containers.
Common Labeling Non-Compliance Issues Identified in Inspections
- Missing local language translation on preprinted labels
- Incorrect label application or orientation (e.g., covering barcodes)
- Translation errors leading to misinterpretation (e.g., “serum” translated as “blood”)
- Inconsistent label formats across regions, causing confusion at central labs
- Use of abbreviations not standardized or explained
In a 2022 EMA inspection, a sponsor was cited for failing to provide sample labels in Hungarian, despite the study being conducted at three sites in Hungary. The deviation triggered a CAPA to revise the global labeling SOP and retrain study teams on country-specific requirements.
Best Practices for Multilingual Labeling Implementation
To avoid such findings, sponsors and CROs should adopt the following practices:
- Use a validated translation vendor with expertise in medical terminology
- Develop label templates that allow dynamic language switching
- Include both English and local language on each label where feasible
- Ensure that any barcodes remain scannable and unblocked
- Train site staff to interpret label content in both languages
Table: Labeling Elements and Language Guidance
| Label Element | Mandatory Language | Notes |
|---|---|---|
| Subject ID | English | Standardized format across all regions |
| Sample Type (e.g., “Plasma”) | English + Local | Dual-language reduces lab errors |
| Collection Date | Numeric format | Use DD-MMM-YYYY for clarity (e.g., 24-AUG-2025) |
| Storage Temperature | English + Local | Include temperature symbol (e.g., “Store at 2–8°C”) |
CAPA Strategy for Labeling Deviations
When deviations are identified—such as using incorrect translations or applying outdated labels—CAPA should include:
- Immediate quarantine of mislabeled samples (if risk is significant)
- Label redesign and translation review
- Re-training of packaging staff and couriers
- Revision of the labeling SOP to include version control and verification steps
- Audit of remaining inventory to detect other affected labels
Tools and Templates for Global Labeling
Some sponsors use centralized labeling portals that offer:
- Drop-down options for language selection
- Pre-translated fields for sample types, handling instructions, and site-specific content
- Built-in label printing with 2D barcodes and sample-specific QR codes
- Version-controlled PDF archives for inspection review
These tools help reduce the risk of manual translation errors and improve efficiency across global study sites.
External Reference
For examples of multilingual label guidelines, refer to the EU Clinical Trials Register at clinicaltrialsregister.eu.
Conclusion
Multilingual labeling is an essential but often overlooked aspect of sample management in global trials. Sponsors must design robust SOPs and systems to ensure translations are accurate, label content is complete, and local requirements are met. With proactive CAPA frameworks and validated tools, organizations can reduce labeling-related non-compliance and improve inspection readiness across their clinical portfolio.